The Weekly Summary

Shkreli TuringDecember 14th – December 20th

In the general news, bogus terrorist bomb threats closed all schools in Los Angeles. Donald Trump stayed in the public spotlight, and the Fed finally raised interest rates by 0.25%.

In healthcare business news, Turing Pharma’s scandalous attention-loving CEO, Martin Shkreli, was arrested for allegedly running a Ponzi scheme using his various hedge funds and companies. Valeant (VRX) stock spiked 20% after analyst day. They also signed a new drug distribution deal with Walgreens (WBA). Lastly, large hospital mergers are getting pushback from the FTC.

On the data front, Bind (BIND) stock tanked on bad data for Accurins to treat lung cancer. Also, Atara (ATRA) also tanked on bad data for myostatin-blocking drug PINTA 745.

From the FDA, Lilly’s (LLY) diabetes drug Basaglar was approved as a cheaper alternative to Sanofi-Aventis’ Lantus. Lastly, the agency will move to ban tanning beds for people under the age of 18.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.